Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Maria J. de Miguel Luken"'
Autor:
Lillian L. Siu, Ina Rhee, Mahrukh Huseni, Jeong Kim, Maria Anderson, Tony Pourmohamad, Eric Stefanich, Shang-Chiung Chen, Deepali Rishipathak, Mario Sznol, Annemie Rutten, Alexander M. Lesokhin, Laura Q. Chow, Andres Cervantes, Wilson H. Miller, Grant A. McArthur, F. Stephen Hodi, D. Ross Camidge, Ahmad Awada, Michael Gordon, Yung-Jue Bang, Michael J. Pishvaian, Maria J. de Miguel Luken, Howard A. Burris, Tae Won Kim
Supplementary Figure from First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22b6273d77c0afd4d20a2feba90f7ac7
https://doi.org/10.1158/1078-0432.22486685
https://doi.org/10.1158/1078-0432.22486685
Autor:
Lillian L. Siu, Ina Rhee, Mahrukh Huseni, Jeong Kim, Maria Anderson, Tony Pourmohamad, Eric Stefanich, Shang-Chiung Chen, Deepali Rishipathak, Mario Sznol, Annemie Rutten, Alexander M. Lesokhin, Laura Q. Chow, Andres Cervantes, Wilson H. Miller, Grant A. McArthur, F. Stephen Hodi, D. Ross Camidge, Ahmad Awada, Michael Gordon, Yung-Jue Bang, Michael J. Pishvaian, Maria J. de Miguel Luken, Howard A. Burris, Tae Won Kim
Supplementary Table from First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c7045a3205e3b86a9869343e3c0f1eb
https://doi.org/10.1158/1078-0432.22486667.v1
https://doi.org/10.1158/1078-0432.22486667.v1
Autor:
Lillian L. Siu, Ina Rhee, Mahrukh Huseni, Jeong Kim, Maria Anderson, Tony Pourmohamad, Eric Stefanich, Shang-Chiung Chen, Deepali Rishipathak, Mario Sznol, Annemie Rutten, Alexander M. Lesokhin, Laura Q. Chow, Andres Cervantes, Wilson H. Miller, Grant A. McArthur, F. Stephen Hodi, D. Ross Camidge, Ahmad Awada, Michael Gordon, Yung-Jue Bang, Michael J. Pishvaian, Maria J. de Miguel Luken, Howard A. Burris, Tae Won Kim
Purpose:OX40, a receptor transiently expressed by T cells upon antigen recognition, is associated with costimulation of effector T cells and impairment of regulatory T-cell function. This first-in-human study evaluated MOXR0916, a humanized effector-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08883569f7378a70e0afe6b174660944
https://doi.org/10.1158/1078-0432.c.6532370
https://doi.org/10.1158/1078-0432.c.6532370
Autor:
Lillian L. Siu, Ina Rhee, Mahrukh Huseni, Jeong Kim, Maria Anderson, Tony Pourmohamad, Eric Stefanich, Shang-Chiung Chen, Deepali Rishipathak, Mario Sznol, Annemie Rutten, Alexander M. Lesokhin, Laura Q. Chow, Andres Cervantes, Wilson H. Miller, Grant A. McArthur, F. Stephen Hodi, D. Ross Camidge, Ahmad Awada, Michael Gordon, Yung-Jue Bang, Michael J. Pishvaian, Maria J. de Miguel Luken, Howard A. Burris, Tae Won Kim
Supplementary Data from First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0528c7584af822078d30d2eaa31153f3
https://doi.org/10.1158/1078-0432.22486697.v1
https://doi.org/10.1158/1078-0432.22486697.v1
Autor:
Tae Won Kim, Howard A. Burris, Maria J. de Miguel Luken, Michael J. Pishvaian, Yung-Jue Bang, Michael Gordon, Ahmad Awada, D. Ross Camidge, F. Stephen Hodi, Grant A. McArthur, Wilson H. Miller, Andres Cervantes, Laura Q. Chow, Alexander M. Lesokhin, Annemie Rutten, Mario Sznol, Deepali Rishipathak, Shang-Chiung Chen, Eric Stefanich, Tony Pourmohamad, Maria Anderson, Jeong Kim, Mahrukh Huseni, Ina Rhee, Lillian L. Siu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Purpose: OX40, a receptor transiently expressed by T cells upon antigen recognition, is associated with costimulation of effector T cells and impairment of regulatory T-cell function. This first-in-human study evaluated MOXR0916, a humanized effector
Autor:
Daniel S. Tan, Toshio Shimizu, Benjamin Solomon, Rebecca S. Heist, Martin Schuler, Maria J. De Miguel Luken, Anas Gazzah, Martin Wermke, Christophe Dooms, Herbert H. Loong, Neeltje Steeghs, Enriqueta Felip, Conor E. Steuer, Eric van Cutsem, Ross A. Soo, Ashley C. Jaeger, Jaeyeon Kim, Kun Xu, Xueying Chen, Xiaoming Cui, Heather Burks, Anna Farago, Philippe A. Cassier
Publikováno v:
Cancer Research. 82:CT033-CT033
Background: KRAS G12C oncogenic mutations occur in ~13% of non-small cell lung cancers (NSCLCs) and up to 4% of other solid tumors. JDQ443 is a selective, covalent, orally bioavailable, investigational KRASG12C inhibitor that irreversibly traps KRASG
Autor:
Benjamin Solomon, Rebecca S Heist, Daniel SW Tan, Philippe A Cassier, Christophe Dooms, Eric Van Cutsem, Conor E Steuer, Neeltje Steeghs, Martin Schuler, Anas Gazzah, Martin Wermke, Enriqueta Felip, Herbert HF Loong, Maria J De Miguel Luken, Ross A Soo, Ashley Jaeger, Kun Xu, Xueying Chen, Xiaoming Cui, Heather Burks, Anna F Farago, Toshio Shimizu
Publikováno v:
Molecular Cancer Therapeutics. 20:LBA038-LBA038
Background Kirsten rat sarcoma virus (KRAS) is a GTPase that regulates cell signaling pathways involved in cell proliferation, survival, and tumorigenesis. Somatic mutations in KRAS resulting in a glycine to cysteine substitution at codon 12 (KRAS G1